Dr. Simon Kennedy

Senior Lecturer
University of Glasgow, United Kingdom

Highest Degree
Ph.D. in Pharmacology from University of Strathclyde, UK

My URL
https://livedna.org/44.6262

Share this Profile

Area of Interest:

Pharmacology and Toxicology
Pharmacology
Heart
Pharmacological Therapeutics
Cardiovascular Research

Selected Publications

  1. Farmer, D.G.S., A.M. Ewart, K.M. Mair and S. Kennedy, 2014. Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hypoxia in the mouse. Pulm. Pharmacol. Ther. (In Press). .

  2. Almabrouk, T.A.M., A.M. Ewart, I.P. Salt and S. Kennedy, 2014. Perivascular fat, AMP-activated protein kinase and vascular diseases. Br. J. Pharmacol. (In Press). .
    Direct Link  |  

  3. Watt, J., S. Kennedy, C.M. McCormick, E.O. Agbani and A. Mullen et al., 2013. Stent-based delivery of succinobucol in a porcine coronary model. Catheter Cardiovasc. Interv., 81: 698-708.

  4. McDonald, R.A., K.M. White, J. Wu, B.C. Cooley and K.E. Robertson et al., 2013. miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. Eur. Heart J., 34: 1636-1643.
    CrossRef  |  PubMed  |  

  5. Kennedy, S., J. Wu, R.M. Wadsworth, C.E. Lawrence and P. Maffia, 2013. Mast cells and vascular diseases. Pharmacol. Ther., 138: 53-65.
    PubMed  |  

  6. Watt, J., F. Greig, M.A. Ewart, R.M. Wadsworth, K.G. Oldroyd and S. Kennedy, 2012. The effect of reactive oxygen species on whole blood aggregation and the endothelial cell-platelet interaction in patients with coronary heart disease. Thromb. Res., 130: 210-215.
    PubMed  |  

  7. Greig, F.H., S. Kennedy and C.M. Spickett, 2012. Physiological effects of oxidized phospholipids and their cellular signalling mechanisms in inflammation. Free Radic. Biol. Med., 52: 262-280.
    PubMed  |  

  8. Ewart, A.M. and S. Kennedy, 2012. Diabetic cardiovascular disease-AMP-activated protein kinase (AMPK) as a therapeutic target. Cardiovasc. Hematol. Agents Med. Chem., 10: 190-211.
    PubMed  |  

  9. Wu, J., R.M. Wadsworth and S. Kennedy, 2011. Inhibition of iNOS promotes vein graft neoadventitial inflammation and remodelling. J. Vasc. Res., 48: 141-149.
    PubMed  |  

  10. Ialenti, A., G. Grassia, P. Gordon, M. Maddaluno and M. Vittoria Di Lauro et al., 2011. Inhibition of in-stent restenosis by oral administration of bindarit in porcine coronary artery. Arterioscler. Thromb. Vasc. Biol., 31: 2448-2454.
    PubMed  |  

  11. Ewart, A.M. and S. Kennedy, 2011. AMPK and vasculoprotection. Pharmacol. Ther., 131: 242-253.
    PubMed  |  

  12. Shedden, L., S. Kennedy, R. Wadsworth and P. Connolly, 2010. Towards a self-reporting coronary artery stent-Measuring neointimal growth associated with in-stent restenosis using electrical impedance techniques. Biosens. Bioelectron., 26: 661-666.
    CrossRef  |  

  13. McCormick, C.M., R.L. Jones, S. Kennedy and R.M. Wadsworth, 2010. Activation of prostanoid EP receptors by prostacyclin analogues in rabbit iliac artery: Implications for anti-restenotic potential. Eur. J. Pharmacol., 641: 160-167.
    PubMed  |  

  14. Mair, K.M., E. Robinson, K.A. Kane, S. Pyne, N.J. Pyne and S. Kennedy, 2010. Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br. J. Pharmacol., 161: 176-192.
    PubMed  |  

  15. Grassia, G., M. Maddaluno, C. Musilli, D. De Stefano and R. Carnuccio et al., 2010. The IκB kinase inhibitor nuclear factor-κB essential modulator-binding domain peptide for inhibition of balloon injury-induced neointimal formation. Arterioscler. Thromb. Vasc. Biol., 30: 2458-2466.
    PubMed  |  

  16. Kennedy, S., K.A. Kane, N.J. Pyne and S. Pyne, 2009. Targeting sphingosine-1-phosphate signalling for cardioprotection. Curr. Opinion Pharmacol., 9: 194-201.
    CrossRef  |  PubMed  |  

  17. Farmer, D.G. and S. Kennedy, 2009. RAGE, vascular tone and vascular disease. Pharmacol. Ther., 124: 185-194.
    PubMed  |  

  18. Watt, J., R.M. Wadsworth, S. Kennedy and K.G. Oldroyd, 2008. Pro-healing drug-eluting stents: A role for antioxidants? Clin. Sci., 114: 265-273.
    PubMed  |  

  19. Tennant, G., R.M. Wadsworth and S. Kennedy, 2008. PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse. Atherosclerosis, 198: 57-64.
    PubMed  |  

  20. Lim, S.Y., C.L. Wainwright, S. Kennedy and K.A. Kane, 2008. Activation of protease activated receptor-2 induces delayed cardioprotection in anesthetized mice. Cardiovasc. Drugs Ther., 23: 519-520.
    PubMed  |  

  21. Erridge, C., S. Kennedy, C.M. Spickett and D.J. Webb, 2008. Oxidised phospholipid inhibition of Toll Like Receptor (TLR) signalling is restricted to TLR2 and TLR4-Roles for CD14, LPS-binding protein and MD2 as targets for specificity of inhibition. J. Biol. Chem., 283: 24748-24759.
    PubMed  |  

  22. Coats, P., S. Kennedy, S. Pyne, C.L. Wainwright and R.M. Wadsworth, 2008. Inhibition of non-Ras protein farnesylation reduces in-stent restenosis. Atherosclerosis, 197: 515-523.
    PubMed  |  

  23. McCormick, C., R.M. Wadsworth, R.L. Jones and S. Kennedy, 2007. Prostacyclin analogues: The next drug-eluting stent? Biochem. Soc. Trans., 35: 910-911.
    PubMed  |  

  24. Maffia, P., B.H. Zinselmeyer, A. Ialenti, S. Kennedy and A.H. Baker et al., 2007. Two-photon microscopy for 3D imaging of lymphocyte recruitment into apolipoprotein E-deficient mouse carotid artery. Circulation, 115: e326-e328.

  25. Kennedy, S., S.G. Burke, A.A. Preston and A.R. McPhaden, 2007. Mechanism underlying the increased sensitivity to nitric oxide donor drugs in balloon-injured pig coronary artery. Endothelium, 14: 105-113.

  26. Dever, G.J., C.L. Wainwright, S. Kennedy and C.M. Spickett, 2007. Phospholipid chlorohydrin induces leukocyte adhesion to ApoE -/- mouse arteries via upregulation of P-Selectin. Free Radic. Biol. Med., 44: 452-463.
    PubMed  |  
Member since January, 2014